CAU
EW icon

Caxton Associates (UK)’s Edwards Lifesciences EW Stock Holding History

Caxton Associates (UK)’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5,110
Closed -$370K – 754
2025
Q1 		$370K Buy
+5,110
New +$366K 0.01% 560

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $113B AUM 36.92% 1-Year Est. Return

Caxton Associates (UK)'s EW Position: Q2 2025 in Review

Caxton Associates (UK) sold out of Edwards Lifesciences (EW) in Q2 2025, closing a stake of 5,110 shares — an estimated $370K sold.

Caxton Associates (UK) first reported a position in EW in Q1 2025 and held it in 1 quarter. The position peaked at $370K in Q1 2025. 1,259 funds tracked by Wall St. Rank hold EW as of Q2 2025.

  • Caxton Associates (UK) reported no remaining Edwards Lifesciences position as of Q2 2025 after selling out during the quarter.
  • Caxton Associates (UK) sold 5,110 Edwards Lifesciences shares in Q2 2025, an estimated $370K.
  • Caxton Associates (UK) first reported a position in Edwards Lifesciences in Q1 2025 and held it in 1 quarter.
  • Caxton Associates (UK)'s Edwards Lifesciences position peaked at $370K in Q1 2025.
  • 1,259 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2025.

Based on Caxton Associates (UK)'s 13F filing for Q2 2025, filed 15 Aug 2025.